U.S. Patent Grants Expanded Protection for EPC Capture Technology


January 7, 2011

January 7, 2011 – The United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of endothelial progenitor cell (EPC) capture technology. It applies to OrbusNeich’s Genous EPC technology.

The patent (U.S. Pat. No. US 7,803,183) covers a coating on an implantable medical device that has one or more layers of a matrix. Incorporated into the matrix are antibodies or antibody fragments that allow for capture in vivo of circulating EPCs.

Genous promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The antibody surface coating attracts EPCs circulating in the blood to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The technology will be used on a next-generation stent platform that combines luminal cell capture with abluminal drug elution and is currently in clinical trial evaluation

For more information: www.OrbusNeich.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.